Testing a T Cell Treatment for People With Glioblastoma
Official title: CARv3-TEAM-E T Cells in Glioblastoma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a treatment made from a person's own immune cells in people with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
Read our full plain-language summary
What the trial team says
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Key facts
- Registry number
- NCT05660369
- Stage of testing
- Phase 1
- Conditions studied
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Where it is running
This trial lists 1 site.
-
Massachusetts
- Massachusetts General Hospital Cancer Center (Boston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.